CERo Therapeutics Holdings, Inc. (CERO)

CERO Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Year	2023	2022	2021
Net Income	-2.54	-0.67	-10.63
Depreciation & Amortization	0	0	0.74
Share-Based Compensation	0	0	0.29
Other Operating Activities	1.01	-0.42	-0.49
Operating Cash Flow	-1.52	-1.09	-10.09
Capital Expenditures	0	0	-0.61
Change in Investments	-7.94	180.84	0
Investing Cash Flow	-7.94	180.84	-0.61
Share Issuance / Repurchase	-33.48	-139.35	0.06
Debt Issued / Paid	0.91	0.65	0
Financing Cash Flow	-32.58	-138.7	0.06
Net Cash Flow	-42.04	41.04	-10.65
Free Cash Flow	-1.52	-1.09	-10.71
Free Cash Flow Per Share	-0.23	-0.05	-1.19

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).